Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of nemolizumab in moderate-to-severe atopic dermatitis
2024-514404-13-00Phase 3Completed
- Sponsor
- Galderma
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Started Oct 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-514404-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514404-13-00.